CFTR and cystic fibrosis: The F508del mutation, which accounts for approximately 70% of CF mutations across the world, results in abnormal folding and trafficking of the CFTR gene to the cell surface and, thus, presents a problem not fully addressed with potentiators such as IVA [6].